Frequently Asked Questions How fast do Lipo-Mino injections work
Nizam AAK, Md Fadilah NI, Ahmad H, Maarof M, Fauzi MB
Modifications to the peptide chain to reduce degradation by DPP-4, combined with acylation to promote non-covalent binding to albumin, resulted in long-acting formulations, enabling their use in clinical practice.3,5 Initially, GLP-1 receptor monoagonists were marketed with the aim of treating type 2 diabetes, harnessing their incretin effect and glucose-dependent mechanism, along with their capacity to reduce body weight and their beneficial effects on associated comorbidities.1,3,5 Subsequently, research shifted its focus to obesity, employing higher doses than those used for diabetes.3,5 This was followed by the development of unimolecular structures with multi-receptor activity, such as GIP/GLP-1 and GLP-1/glucagon (GCG) coagonists, as well as GIP/GLP-1/GCG triagonists
On one hand, they are implicated in neurodegeneration through their ability to generate ROS, which can further damage cellular structures and impair neuronal activity
GLP-1 release depends on communication between your gut and brain